CN101406613B - Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis - Google Patents
Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis Download PDFInfo
- Publication number
- CN101406613B CN101406613B CN2007101395658A CN200710139565A CN101406613B CN 101406613 B CN101406613 B CN 101406613B CN 2007101395658 A CN2007101395658 A CN 2007101395658A CN 200710139565 A CN200710139565 A CN 200710139565A CN 101406613 B CN101406613 B CN 101406613B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- draconis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 208000009525 Myocarditis Diseases 0.000 title abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 206010047470 viral myocarditis Diseases 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 241001489978 Eupolyphaga Species 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- -1 filters Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- 206010001115 Adams-Stokes syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000661 pacemaking effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of a traditional Chinese medicine composition to the preparation of medicaments for treating vital myocarditis. The clinical trials prove that the medical composition consists of more than ten traditional Chinese medicines such as ginseng, radix ophiopogonis, Chinese Magnoliavine Fruit, dogwood, Semen Ziaiphi Spinoae, Herba Taxilli, radix salvia miltrorrhiza and so on, has good improving function on palpitation, chest distress, precordium dull pain, hypodynamia and other symptoms of clinical vital myocarditis through supplementing qi and nourishing yin, and removing heat and dissolving stasis, has no toxic side effects clinically and good obedience and clinical effects, and is worthy of popularization.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, the present invention relates to the application of a kind of Chinese medicine composition in preparation treatment viral myocarditis medicine, belong to the Chinese medicine application.
Background technology
Viral myocarditis is that virus infringement heart causes that the myocarditis sexually transmitted disease (STD) becomes the disease of main performance.The most common with the various viral infection that cause intestinal and upper respiratory tract infection.Enterovirus is a pico+ribonucleic acid+virus, wherein with enterovirus COxsackie, dust can, poliovirus is for causing myocarditic main virus; The leaf that myxovirus such as influenza virus, parainfluenza virus cause is not rare, the myocarditis that adenovirus also can cause, and in addition, measles, parotitis, encephalitis b, hepatitis, cytomegalovirus all may cause myocarditis.Wherein, the coxsackie B group is the first pathogen of people body-centered myositis, sees that so that 2,4 liang of groups more 5,3,1 takes second place according to its typing; 1,4,9,16,23 various easy infringement babies of A group invade and adult cardiomyocytes once in a while.
The primary disease extent of disease is not of uniform size, can be diffusivity or limitation.Can be acute or chronic with course of disease development.The heavier person's naked eyes of pathological changes see that cardiac muscle is very lax, gray or yellow, and the chambers of the heart enlarges.Pathological changes does not have discovery than the lighter when checking substantially, only find and the diagnosis of relying to some extent at microscopically, and pathological examination must be in the section of a plurality of positions, and the side makes pathological changes avoid omitting.At microscopically, can find cellular infiltration between the cardiac muscle fiber with in the blood vessel connective tissue all around, based on mononuclear cell.Myocardial cell can have degeneration, dissolving or necrosis.Pathological changes becomes viral perimyocarditis as then merging pericarditis at the pericardium inferior segment.Pathological changes can relate to a cardiac muscle and a matter, also can relate to pace-making and conducting system such as sinuatrial node, atrioventricular node, atrioventricular bundle and the bundle branch of heart, becomes ARR pathogenesis basis.The virulence of virus is strong more, and extent of disease is wide more.In experimental myocarditis, can see myocardial necrosis afterwards by fibrous tissue replacement.
The symptom of viral myocarditis may come across the symptom phase or the convalescent period of protopathy.As occurring in symptom phase of protopathy, its performance can be covered by protopathy.Most of patients has symptoms such as heating, systemic pain, pharyngalgia, diarrhoea at premorbid, reflection general viral infection, but part patient protopathy mild symptoms is also arranged and not remarkable, and carefully the side of questioning closely is noted, the myocarditis symptom is then relatively significantly.That myocarditis patient often tells is uncomfortable in chest, pareordia dull pain, cardiopalmus, weak, nauseating, dizzy.Clinically in Zhen Duan the myocarditis, about 90% are chief complaint or head sees symptom with arrhythmia, and wherein small number of patients can take place to faint or Adams Stokes syndrome therefrom.Only a few patient rises after being ill, and development heart failure or cardiogenic shock occur rapidly.(Chen Haozhu. practical internal medicine. People's Health Publisher .1997 July the 10th edition)
The present invention is the improvement invention of carrying out on the basis of ZL02146572.X patent application, quotes in full the content of this patent document record at this.The invention provides the new application of a kind of Chinese medicine composition in the medicine of preparation treatment viral myocarditis, prove by clinical trial, this pharmaceutical composition has good improvement effect to the cardiopalmus of viral myocarditis clinically, uncomfortable in chest, pareordia dull pain, disease such as weak, and do not find toxic and side effects in clinical, have good compliance and clinical effectiveness, be worth clinical expansion.
Summary of the invention
The purpose of this invention is to provide the application of this Chinese medicine composition in preparation treatment viral myocarditis medicine.It is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of crude drug is preferably in the Chinese medicine composition of the present invention:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters spissated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, spissated extractum.
E) with step b) and d) merging of gained extractum, the fine drug powder of adding step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
In the application of the present invention, described Chinese medicine composition is a capsule, tablet, electuary, a kind of in powder or the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
Viral myocarditis belongs to categories such as the Chinese medicine thoracic obstruction, cardiopalmus, epidemic febrile disease.Its pathogenesis is to invade in the pyretic toxicity, consumes sad battalion, so that insufficiency of heart-QI, deficiency of heart-yin, the resistance of the heart arteries and veins stasis of blood.According to its pathogenesis, with nutrition with improve cardiac muscle and cardiac function, enhancing body autoimmunity cooperates Chinese medicine composition supplementing QI and nourishing YIN heat clearing and blood stasis dispersing comprehensive treatment of the present invention to execute to control.Chinese medicine composition of the present invention is made up of ten pleasant impression Chinese medicines such as Radix Ginseng, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Fructus Corni, Semen Ziziphi Spinosae, Herba Taxilli, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Nardostachyos, Rhizoma Coptidis, Os Draconis, wherein Radix Ginseng, Radix Ophiopogonis, Fructus Schisandrae Chinensis have the effect of Qi-benefiting and heart-nourishing the moon, add Semen Ziziphi Spinosae, the Os Draconis mind calming is throbbed with fear surely, Fructus Corni, Herba Taxilli (modern study has the effect of coronary dilating, decreasing heart rate) invigorating the liver and kidney are to consolidate, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Nardostachyos are with benefiting QI for activating blood circulation, Rhizoma Coptidis is with the pathogenic fire purging mind calming, the merit of play Qi-benefiting and heart-nourishing altogether, the mind calming of invigorating blood circulation being throbbed with fear surely.The valerone that contains in the modern pharmacological research Radix Et Rhizoma Nardostachyos has membrane stabilizing action, and energy over reach potential time interrupts reciprocal excitation, therefore can effectively treat arrhythmia such as premature beat; The berberine that contains in the Rhizoma Coptidis has the effect of treatment tachy-arrhythmia; The cardiopalmus of viral myocarditis clinically, uncomfortable in chest, pareordia dull pain, disease such as weak there are good improvement effect, and do not find toxic and side effects in clinical, have good compliance and clinical effectiveness, be worth clinical expansion.
Essence is for a better understanding of the present invention observed Chinese medicine composition of the present invention " treatment viral myocarditis " result of the test (used medicine is for pressing the prepared capsule of embodiment 1 method) below by clinical experiment
Experimental example: (this test data derives from Hebei Yi Ling hospital)
Summary: purpose is observed the curative effect of traditional Chinese medicine composition for treating viral myocarditis of the present invention.Method is divided into treatment group and each 50 example of observation group at random with 100 routine viral myocarditis patients.Observation group adopts the doctor trained in Western medicine conventional therapy, and the treatment group adds on the observation group basis uses traditional Chinese medicine composition for treating of the present invention.Every day three times, each 4,15 is 1 course of treatment.The total effective rate of treatment group as a result is 98.0%, and 86.0%, two group of comparing difference of matched group total effective rate is remarkable.The treatment group was cured the case average cure time 24.5 days, and matched group average time is 36 days, and two groups of comparing differences are (P＜0.05) obviously.It is little that conclusion is used traditional Chinese medicine composition for treating viral myocarditis toxic and side effects of the present invention, and curative effect is reliable and secure.
Physical data: we in year August in April, 2006 to 2007 with 100 routine viral myocarditis patient random packet.50 examples are organized in treatment: male 32 examples, women 18 examples; Age 5-10 year 3 examples, 11-15 year 18 examples, 16-20 year 16 examples, 〉=21 years old 13 example.Matched group 50 examples: male 31 examples, women 19 examples; Age 5-10 year 2 examples, 11-15 year 18 examples, 16-20 year 15 examples, 〉=21 years old 15 example.The difference (P＞0.05) of handling that there are no significant is learned in two groups of case sexes, age, pathogenic factor and clinical diagnosises by statistics, has comparability.
Diagnostic criteria: make a definite diagnosis according to " adult's acute viral myocarditis diagnosis reference standard " (draft) that nineteen ninety-five whole nation myocarditis cardiomyopathy symposium proposes.
Therapeutic Method: two groups of cases all give general treatment (lie up, high protein, homovitamin light diet) and Drug therapy and add magnesium polarized solution (10% potassium chloride 10ml, insulin 12U after being admitted to hospital; 25% magnesium sulfate 10ml) adds quiet of 10% glucose 500ml, every day 1 time, logotype 10-14 days.Quiet of Oleum Curcumae 250ml and cytosine arabinoside 50-100mg, every day 1 time, logotype 7 days.Interferon 5-10 ten thousand U intramuscular injection, every day 1 time.Can add with broad ectrum antibiotic treatment as concurrent infection, as arrhythmia occur and can select the antiarrhythmic drug symptomatic treatment for use.The treatment group adds with Chinese medicine composition of the present invention (making by embodiment 1 method) oral on the basis of above-mentioned treatment, and every day three times, each 4,15 is 1 course of treatment.
Criterion of therapeutical effect: cure: symptom, signs such as uncomfortable in chest, cardiopalmus and pareordia dull pain disappear, and serum zymetology (CKLDH) checks and recover normal fully that Electrocardioscopy T ripple, ST section and abnormality Q wave recover normal substantially.Produce effects: clinical symptoms, sign obviously alleviate, and Serological testing recovers normally substantially, and Electrocardioscopy T ripple and ST section before are clearly better or recover normal substantially.Effectively: symptom, sign alleviate before the treatment to some extent, and the serum enzyme labeled compound assay before is clearly better, and Electrocardioscopy T ripple and ST section and abnormality Q wave make moderate progress when falling ill.Invalid: clinical symptoms, sign, serum enzyme labeled compound assay and Electrocardioscopy all do not have improvement.
Therapeutic outcome: two groups of curative effects relatively see Table 1
Table 1 liang group curative effect comparison (n, %)
| Group | n | Recovery from illness | Produce effects | Effectively | Invalid | Rate is always arranged |
| The treatment group | 50 | 36(72.0) | 9(18.0) | 4(8) | 1(2) | 98.0 |
| Matched group | 50 | ?19(38) | 15(30) | 8(16) | 7(14) | 86.0 |
Compare P＜0.05 with matched group
Compare two groups of courses of treatment: the treatment group is cured 36 examples, average cure time 24.5 days; Matched group is cured 19 examples, average cure time 36 days.Two groups are compared P＜0.05, have significant difference, illustrate that the treatment group obviously is better than matched group.
Three, conclusion
By above result of study, the capsule made of the present invention is applied to the treatment of viral myocarditis as can be seen, has obtained satisfied effect, and the result shows and takes the capsule for treating viral myocarditis patient that the present invention makes, can obviously improve clinical symptoms, untoward reaction is few.
The specific embodiment
Medicine of the present invention is to be prepared from by following examples, and following specific embodiment is an explanation of the invention.
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as capsule
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into fine powder, and is standby;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, and reclaims ethanol, concentrate extractum, standby;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is standby;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and the extracting solution of filtrate and Fructus Schisandrae Sphenantherae etc. merges, and concentrated extractum is standby;
E) with step b) and d) merging of gained extractum, the fine drug powder that adds the step c) gained is dried, and is ground into fine powder, adds step a) gained fine drug powder, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Claims (6)
1. the application of Chinese medicine composition in preparation treatment viral myocarditis medicine is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. as each described application among the claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates oven dry, the fine powder that is ground into; B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters spissated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker; D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, spissated extractum;
E) with step b) and d) merging of gained extractum, the fine drug powder of adding step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. as each described application among the claim 1-4, it is characterized in that the preparation formulation of described Chinese medicine composition is a kind of in capsule, tablet, electuary, powder or the oral liquid formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101395658A CN101406613B (en) | 2007-10-11 | 2007-10-11 | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101395658A CN101406613B (en) | 2007-10-11 | 2007-10-11 | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101406613A CN101406613A (en) | 2009-04-15 |
| CN101406613B true CN101406613B (en) | 2011-11-09 |
Family
ID=40569958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101395658A Active CN101406613B (en) | 2007-10-11 | 2007-10-11 | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406613B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038856B (en) * | 2009-10-13 | 2012-09-05 | 北京以岭药业有限公司 | Content measuring method for four components in Chinese medicinal composition |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947301B (en) * | 2010-09-03 | 2012-01-25 | 南方医科大学 | Medicine composition for preventing and treating vital myocarditis and preparation method thereof |
| CN103623216A (en) * | 2013-12-13 | 2014-03-12 | 李轩辕 | Traditional Chinese medicinal preparation for treating children's virus myocarditis |
| CN113440574B (en) * | 2020-03-25 | 2023-10-20 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating viral myocarditis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2007
- 2007-10-11 CN CN2007101395658A patent/CN101406613B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038856B (en) * | 2009-10-13 | 2012-09-05 | 北京以岭药业有限公司 | Content measuring method for four components in Chinese medicinal composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101406613A (en) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111110824B (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN111249390A (en) | Forsythia-astragalus root compound preparation and preparation method and application thereof | |
| CN101406613B (en) | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis | |
| CN101757409B (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating silicosis | |
| CN100479825C (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN1969940A (en) | Antivirus pharmaceutical composition | |
| CN102908513A (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101637533B (en) | Application of Chinese medicinal composition in preparation of medicament for treating virus myocarditis | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN105079438B (en) | A kind of pharmaceutical preparation for treating vital myocarditis | |
| CN101590178B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating refractory premature beat of elderly patient | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| CN102895513B (en) | Application of Chinese medicine composition in preparing medicines for treating viral myocarditis | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN106361889B (en) | Nourishing heart tune kidney particle and its preparation method and application | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN117482167A (en) | Traditional Chinese medicine composition for treating lung infection related to AIDS and traditional Chinese medicine preparation thereof | |
| CN106266307B (en) | Ant bear gall pill and its preparation method and application | |
| CN102210806A (en) | Application of Chinese medicinal composition to preparation of medicaments for treating nonorganic heart disease arrhythmia | |
| CN102380030B (en) | TCM composition applied to preparation of medication for treating siriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231129 Address after: 102600 17 Tianfu street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: BEIJING YILING PHARMACEUTICAL Co.,Ltd. Address before: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee before: HEBEI YILING MEDICINE RESEARCH INSTITUTE Co.,Ltd. |